Search results for "digestive"

showing 10 items of 2631 documents

MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome

2007

The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) plays a pivotal role in alkylating drug resistance. Here, we determined MGMT activity in primary and recurrent glioblastomas (GBM, WHO grade IV) of patients who received radiation therapy (RT) or RT plus chemotherapy with alkylating agents (temozolomide, chloroethylnitrosoureas). The mean MGMT activity of untreated GBM was 37 +/- 45 (range 0-205) fmol/mg proteins. In the 1st, 2nd and 3rd recurrences, MGMT activity increased from 66 +/- 50 (13-194) to 68 +/- 44 (14-143) and 182 +/- 163 (64-423) fmol/mg protein, respectively. Comparing patients who received RT only with RT plus chemotherapy, a significant increase of MGMT …

Cancer ResearchPathologymedicine.medical_specialtyChemotherapyTemozolomideMethyltransferasemedicine.medical_treatmentCancerBiologymedicine.diseasePrimary tumordigestive system diseasesRadiation therapyOncologymedicineCancer researchneoplasmsSurvival analysismedicine.drugAlkyltransferaseInternational Journal of Cancer
researchProduct

O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts

1998

The DNA repair protein O6-methylguanine-DNA methyl-transferase (MGMT) is a main determinant of resistance of cells to the cytostatic effects of O6-alkylguanine-generating alkylating agents. The purpose of our study was to assay MGMT activity in cells of lung cancers and to correlate MGMT levels with chemotherapy response to cyclophosphamide (CTX) and cisplatin (DDP). MGMT levels were determined in 14 human lung tumor xenografts. There was a wide variation of MGMT expression in these tumors, ranging from 10 to 984 fmol/mg protein. There was also a wide range in the sensitivity of the xenografts to CTX and DDP, as measured by specific growth delay. When the MGMT levels of the different xenogr…

Cancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsMethyltransferaseCyclophosphamidemedicine.medical_treatmentTransplantation HeterologousMice NudeAntineoplastic AgentsBiologyMiceO(6)-Methylguanine-DNA Methyltransferasechemistry.chemical_compoundIn vivoCarcinoma Non-Small-Cell LungCarcinomamedicineAnimalsHumansCyclophosphamideneoplasmsCisplatinChemotherapyDose-Response Relationship DrugO-6-methylguanine-DNA methyltransferasemedicine.diseasedigestive system diseasesNitrogen mustardOncologychemistryCancer researchFemaleCisplatinmedicine.drugInternational Journal of Cancer
researchProduct

Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

2004

Cathepsin D is a lysosomal acid proteinase which is involved in the malignant progression of breast cancer and other gynecological tumors. Clinical investigations have shown that in breast cancer patients cathepsin D overexpression was significantly correlated with a shorter free-time disease and overall survival, whereas in patients with ovarian or endometrial cancer this phenomenon was associated with tumor aggressiveness and a degree of chemoresistance to various antitumor drugs such as anthracyclines, cis-platinum and vinca alkaloids. Therefore, a lot of research has been undertaken to evaluate the role and the prognostic value of cathepsin D also in other solid neoplasms. However, conf…

Cancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsSkin NeoplasmsCathepsin DAntineoplastic AgentsBiologyDigestive System NeoplasmsCathepsin DMetastasisCentral Nervous System NeoplasmsBreast cancerSurgical oncologyNeoplasmsmedicineBiomarkers TumorNeoplasmHumansClinical significanceThyroid NeoplasmsMelanomaEndometrial cancerGeneral Medicinecathepsin D lysosomal proteinases matrix-metalloproteinases metastasis neoplasm plasminogen activator prognosis tumor progressionmedicine.diseaseNeoplasm ProteinsOncologyTumor progressionHead and Neck NeoplasmsDrug DesignCancer researchDisease ProgressionLysosomesUrogenital NeoplasmsClinicalexperimental metastasis
researchProduct

Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer.

1999

The DNA-repair protein O(6)-methylguanine-DNA methyltransferase (alkyltransferase; MGMT) is a major determinant of resistance of cells to various alkylating cytostatic drugs. Its expression in tissues is highly variable, indicating complex regulatory mechanisms involved. Transfection-mediated expression of wild-type p53 has been shown to negatively regulate basal promoter activity of MGMT in vitro. To elucidate whether p53 is involved in regulation of MGMT in tumor tissue, we examined MGMT expression and the p53 status of 140 primary ovarian carcinomas and analyzed the data as to the correlation between MGMT and p53, as well as the survival response of the patients after chemotherapy. We sh…

Cancer ResearchPathologymedicine.medical_specialtyMethyltransferaseTime FactorsCyclophosphamidemedicine.medical_treatmentBiologyDisease-Free Survivalchemistry.chemical_compoundO(6)-Methylguanine-DNA MethyltransferasePredictive Value of TestsmedicineHumansneoplasmsNeoplasm StagingRetrospective StudiesOvarian NeoplasmsChemotherapyL-Lactate DehydrogenaseCancermedicine.diseaseGenes p53ImmunohistochemistrySurvival Analysisdigestive system diseasesNitrogen mustardCarboplatinOncologychemistryCancer researchFemaleTumor Suppressor Protein p53Ovarian cancermedicine.drugAlkyltransferaseFollow-Up StudiesInternational journal of cancer
researchProduct

Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).

2019

11032 Background: GISTs are the most common mesenchymal tumors of the digestive tract. As of recent, new links are being made between GISTS and secondary malignancies. However, whether the coexistence of GISTs with other tumors is stochastic, or the result of related pathogenetic mechanisms is still unknown. Methods: We retrospectively reviewed clinical and molecular features from all GIST patients with second tumors treated in seven Italian GIST reference centers. Qualitative variables were compared using the Fisher exact test. Results: Clinical data of 184 patients with diagnosis of GIST were evaluated. Median age at diagnosis was 66 years, KIT exon 11 resulted the most frequent mutation…

Cancer ResearchPathologymedicine.medical_specialtyOncologybusiness.industryMesenchymal stem cellmedicineGIST - Gastrointestinal stromal tumorDigestive tractIn patientbusinessneoplasmsdigestive system diseasesJournal of Clinical Oncology
researchProduct

Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma

2005

Defects in apoptosis signaling in hepatocytes contribute to tumorigenesis in hepatocellular carcinoma (HCC). In addition, treatment with chemotherapeutic drugs is often ineffective in HCC patients due to the apoptosis resistance of cancer cells. Anti-apoptotic members of the Bcl-2 family, including myeloid cell leukemia-1 (Mcl-1), which regulate intrinsic apoptosis induction at the mito-chondrial level, are often overexpressed in human cancer, and are implicated with disease grade and prognosis. Yet, little is known about the role of Mcl-1 in HCC. In this study, we analyzed the relevance of Mcl-1 expression for the apop-tosis resistance of human HCC. Mcl-1 protein expression was considerabl…

Cancer ResearchProgrammed cell deathCarcinoma HepatocellularApoptosisBiologyPhosphatidylinositol 3-KinasesEpidermal growth factorhemic and lymphatic diseasesTumor Cells CulturedmedicineHumansneoplasmsProtein kinase BPI3K/AKT/mTOR pathwayAkt/PKB signaling pathwayGene Expression ProfilingLiver NeoplasmsIntrinsic apoptosisPrognosisdigestive system diseasesNeoplasm ProteinsProto-Oncogene Proteins c-bcl-2OncologyImmunologyCancer cellCancer researchMyeloid Cell Leukemia Sequence 1 ProteinHepatocyte growth factorProto-Oncogene Proteins c-aktmedicine.drugInternational Journal of Oncology
researchProduct

Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vector…

2001

Autonomous parvoviruses preferentially replicate in and kill in vitro–transformed cells and reduce the incidence of spontaneous and implanted tumors in animals. Because of these natural oncotropic and oncolytic properties, parvoviruses deserve to be considered as potential antitumor vectors. Here, we assessed whether parvovirus H1 is able to kill human hepatoma cells by induction of apoptosis but spares primary human liver cells, and whether the former cells can efficiently be transduced by H1 virus–based vectors. Cell death, infectivity, and transgene transduction were investigated in Hep3B, HepG2, and Huh7 cells and in primary human hepatocytes with natural and recombinant H1 virus. All h…

Cancer ResearchProgrammed cell deathCarcinoma HepatocellularParvovirus H-1Cell SurvivalvirusesGenetic VectorsApoptosisVirus ReplicationVirusCell LineParvoviridae InfectionsParvovirusTransduction (genetics)Transduction GeneticTumor Cells CulturedHumansMolecular BiologybiologyParvovirusLiver NeoplasmsGene Transfer Techniquesbiology.organism_classificationVirologyMolecular biologydigestive system diseasesOncolytic virusCell killingApoptosisDNA ViralHepatocytesMolecular MedicineCancer gene therapy
researchProduct

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

2014

Contains fulltext : 137861.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last 20years; however considerable variation still exists in cancer management and outcome between European countries. Large variation is also apparent between national guidelines and patterns of cancer care in Europe. Therefore, EURECCA, which is the acronym of European Registration of Cancer Care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012, the first multidisciplinary consensus conference about…

Cancer ResearchQuality Assurance Health CareColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Delphi methodSurgical oncologyFAMILIAL ADENOMATOUS POLYPOSISTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]MedicineSHORT-COURSE RADIOTHERAPYRectal cancerQuality assurance; Colon cancer; Rectal cancer; Multidisciplinary teams; Consensus; Delphi method; Audit; Neoadjuvant treatment; Adjuvant treatment; SurgerySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIADisease ManagementPHASE-III TRIALRANDOMIZED CONTROLLED-TRIALNeoadjuvant TherapyQuality assuranceColon cancerEuropemedicine.anatomical_structureTreatment OutcomeOncologyTRANSANAL ENDOSCOPIC MICROSURGERYColonic NeoplasmsPractice Guidelines as TopicHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPYmedicine.medical_specialtyNeoadjuvant treatmentEvidence-based practiceConsensusLYMPH-NODE EVALUATIONDelphi methodRectumAuditSDG 3 - Good Health and Well-beingHumansCIRCUMFERENTIAL RESECTION MARGINddc:610business.industryRectal NeoplasmsTOTAL MESORECTAL EXCISIONCancerLONG-TERM SURVIVALAuditAdjuvant treatmentmedicine.diseaseSurgeryOncology nursingFamily medicineSurgeryMultidisciplinary teamsbusiness
researchProduct

Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway.

2014

Peripheral T-cell lymphomas not otherwise specified (PTCL/NOS) are very aggressive tumors characterized by consistent aberrant expression of platelet-derived growth factor receptor alpha (PDGFRA). In this study, we aimed to identify the determinants of PDGFRA activity in PTCL/NOS and to elucidate the biological consequences of its activation. We observed overexpression of the PDGFRA gene by gene expression profiling in most of the tested PTCLs and confirmed the expression of PDGFRA and phospho-PDGFRA using immunohistochemistry. The integrity of the PDFGRA locus was demonstrated using several different approaches, including massive parallel sequencing and Sanger sequencing. PDGF-AA was found…

Cancer ResearchReceptor Platelet-Derived Growth Factor alphamedicine.medical_treatmentT celltumor cell proliferationPDGFRAGrowth factor receptorCell Line TumormedicinePDFGRASTAT5 Transcription FactorHumansAutocrine signallingExtracellular Signal-Regulated MAP KinasesSTAT5PTCL/NOS; PDFGRA; tumor cell proliferationCell ProliferationPlatelet-Derived Growth FactorbiologyCell growthExtracellular Signal-Regulated MAP KinaseGrowth factorLymphoma T-Cell PeripheralHematologyPTCL/NOSdigestive system diseasesGene expression profilingAutocrine Communicationmedicine.anatomical_structureAnesthesiology and Pain MedicineSTAT1 Transcription FactorOncologyCancer researchbiology.proteinT-cell lymphomaProto-Oncogene Proteins c-aktHuman
researchProduct

Pharmacological targeting of the novel β-catenin chromatin-associated kinase p38α in colorectal cancer stem cell tumorspheres and organoids

2021

AbstractThe prognosis of locally advanced colorectal cancer (CRC) is currently unsatisfactory. This is mainly due to drug resistance, recurrence, and subsequent metastatic dissemination, which are sustained by the cancer stem cell (CSC) population. The main driver of the CSC gene expression program is Wnt signaling, and previous reports indicate that Wnt3a can activate p38 MAPK. Besides, p38 was shown to feed into the canonical Wnt/β-catenin pathway. Here we show that patient-derived locally advanced CRC stem cells (CRC-SCs) are characterized by increased expression of p38α and are “addicted” to its kinase activity. Of note, we found that stage III CRC patients with high p38α levels display…

Cancer ResearchSettore MED/06 - Oncologia Medicapost-translationalImmunologyPopulationSynthetic lethalityArticleCellular and Molecular NeuroscienceCancer stem cellchromatin; colorectal neoplasms; humans; mitogen-activated protein kinase 14; neoplastic stem cells; organoids; prognosis; protein processing post-translational; beta cateninMedicineKinase activitycolon cancer p38 cancer stem cellslcsh:QH573-671educationhumansmitogen-activated protein kinase 14organoidsTrametinibSettore MED/04 - Patologia Generaleeducation.field_of_studybusiness.industrylcsh:CytologyCancer stem cellsneoplastic stem cellsWnt signaling pathwayprotein processingCell Biologycolorectal neoplasmsColorectal cancerdigestive system diseasesSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaCateninCancer researchbeta cateninchromatinprognosisStem cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratoriobusinessProtein Processing Post-TranslationalPost-translational modifications
researchProduct